Sanofi: Diverse Drug Portfolio & Future Pipeline, 4% Dividend …
1 day ago · A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age."
Sanofi Cancels Consumer Healthcare Business Spin-Off - Forbes
Oct 30, 2024 · Sanofi’s decision to cancel the spin-off of its consumer healthcare business and go ahead with a sell a 50% stake to CD&R reflects a strategic shift aimed at focusing more on its core ...
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment ...
1 day ago · Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA’s (NASDAQ: SNY) Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic ...
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a …
1 day ago · Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight PR Newswire Tue, Nov 12, 2024, 5:31 PM 10 ...
Sanofi US News
Sep 27, 2024 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine …
On Friday, Sanofi SA (NASDAQ: SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency. The company ...
Sanofi pushes ahead with €20bn consumer healthcare spin-off
Jun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Press Room - Sanofi US News
Oct 16, 2024 · FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals. Read more.
Press Room - Sanofi US News
Apr 27, 2023 · Sanofi completes acquisition of Provention Bio, Inc. Paris, April 27 2023. Sanofi announced today the completion of its acquisition of Provention Bio, Inc. (“Provention Bio”). The acquisition adds TZIELD (teplizumab-mzwv), an innovative, fully owned, first-in-class therapy in type 1 diabetes to Sanofi’s core asset portfolio in General ...
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment
1 day ago · Regeneron Pharmaceuticals Inc REGN and Sanofi SA’s SNY Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic dermatitis seven years ago.
- Some results have been removed